CD47 and acute myeloid leukemia: The main purpose of these Phase I clinical trials is to check biosafety/tolerability of a CD47 antibody CC-90002 and find an optimal dose for treatment of advanced hematological neoplasms in combination with Rituximab, an anti-CD20 monoclonal antibody (trial NCT02367196) or for monotherapy of acute myeloid leukemia and high-risk myelodysplastic syndrome (trial NCT02641002).